Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced ...

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...

added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema ...

Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.